Additional Zyflamend Research.
New York, NY, December 13, 2002 A new study from the Department of Urology at Columbia University suggests that Zyflamend, an herbal COX-2 inhibiting formulation, strongly suppresses the proliferation of human LNCaP prostate cancer cells and induces a process called apoptosis, a desirable self-destruction of those cancer cells. The study, entitled Zyflamend, an Herbal COX-2 Inhibitor with In Vitro Anti-Prostate Cancer Activity, will be presented at the December 13 meeting of the Society of Urologic Oncology at the National Institutes of Health in Bethesda, Maryland. This meeting is co-sponsored by the National Cancer Institute.
According to researchers, Zyflamend's effects were found to be significantly more potent than a compound in the spice turmeric called curcumin, which is believed by many researchers to be one of the most promising molecules for the prevention and treatment of cancer. Compared to Zyflamend, curcumin exhibited no COX-2 inhibiting effect on its own, suggesting that there is something in the complexity of the whole-plant formulation that is responsible for its pronounced anti-inflammatory effect. Zyflamend was found to be almost equivalent in its COX-2 inhibiting activity to the pharmaceutical selective COX-2 inhibitor NS-398.
This study on Zyflamend is exceptionally promising. This is the first known natural blend of botanicals that is showing COX-2 inhibitory activity, said Aaron Katz, M.D., Director of the Center for Holistic Urology at Columbia-Presbyterian Medical Center. Dr. Katz is the lead researcher on the Zyflamend study to be presented at the NCI Urologic Oncology conference. Our research is on-going and will proceed to clinical trials on Zyflamend's efficacy for prevention and treatment of prostate cancer. By the age of seventy, over seventy percent of men in the U.S. will develop prostate cancer, and men today face treatment options which may have potential side-effects. The need for effective natural therapy has never been greater.
Zyflamend, formulated by New Chapter, Inc., Brattleboro, Vermont, contains ten potency-assured and broad spectrum extracts of COX-2 inhibiting herbs turmeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread, barberry, oregano, rosemary and Scutellaria baicalensis. Zyflamend utilizes supercritical extraction, an innovative technology for extracting herbs at low temperature without the use of industrial chemical solvents. The delicate, volatile, and potentially active constituents of the herbs are thus left undisturbed. The supercritical extraction of Zyflamend is done in a pharmaceutical-grade laboratory in Germany operating in compliance with strict government standards.
For more information on Dr. Katz's research, please contact Dean Draznin Communications, 641-472-2257 or 561-445-8715. See study abstract below.
# # #
ZYFLAMEND, AN HERBAL COX-2 INHIBITOR WITH IN VITRO ANTI-PROSTATE CANCER ACTIVITY
D.L. Bemis, K.A. Kozakowski, A.G. Anastasiadis, B.C. Stisser, L. Salomon, A.E. Katz, Department of Urology, Columbia University, New York, USA.
Purpose: Elevated expression of COX-2, the inducible cyclooxygenase isoform, has been observed in a variety of tumors including prostate cancer and several clinical trials are currently evaluating COX-2 inhibitors for prostate cancer. We are studying a unique preparation (Zyflamend) comprised of ten different standardized herbal extracts (rosemary, tumeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread, barberry, oregano, and scutallaria baicalensis) for COX-2 and growth inhibitory activities in the LNCaP human prostate cancer cell line.
Methods: Zyflamend was provided by the manufacturer, New Chapter, Inc. (Brattleboro, VT). A series of dilutions was prepared in DMSO and the dilutions were added to LNCaP growth medium so that all doses tested had equivalent (0.1%) DMSO levels. Cell growth curves were done by counting cells at 24, 48, and 72 hr and were compared to control cells treated at the same times with 0.1% DMSO alone. Apoptosis in these cultures was evaluated by Western blot analysis of PARP cleavage and measurement of caspase-3 activity using a colorimetric substrate assay. Effects on purified COX-2 enzyme activity was measured using a colorimetric assay (Cayman Chemicals, Ann Arbor), and effects on COX-2 protein expression was determined via Western blot analysis of protein extracts from treated cells. These activities were also compared to the effects of purified curcumin (dissolved in DMSO) at levels equivalent to those that would be found in Zyflamend, at similar doses.
Results: LNCaP cell growth was suppressed by Zyflamend extracts and by 72 hrs there was a significant reduction (78%) in cell number in Zyflamend-treated cultures (7.9x104 vs 3.53x105 cells / well, p ≤, 0.01) compared to controls. PARP cleavage fragments were evident and caspase-3 activity was upregulated 2-fold by 72 hr treatment, demonstrating a potential apoptotic effect of this substance that was not found in controls. COX-2 activity was also significantly decreased in the presence of the herbal extract, while equivalent doses of curcumin alone did not inhibit COX-2 in the assay utilized. COX-2 protein expression in LNCaP cells was not affected by the agent.
Conclusions: Our results suggest that Zyflamend, an herbal extract and COX-2 inhibitor, strongly suppresses LNCaP cells and induces apoptosis. These effects appear to be more potent that those observed with curcumin alone. We are pursuing further in vitro and in vivo studies to determine if Zyflamend could be an effective prostate cancer chemopreventative supplement.
|This article was published on Tuesday 12 September, 2006.|
|Current Reviews: 0|